Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486)

Growth Hormone and IGF Research

Volumn 15, Issue 2, 2005, Pages 140-147

  Milewicz, Tomasz ^a   Gregoraszczuk, Ewa Lucja ^b   Sztefko, Krystyna ^a   Augustowska, Katarzyna ^b   Krzysiek, Józef ^a   Ryś, Janusz ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Human breast cancer; IGF I; IGFBP

Indexed keywords

ANTIESTROGEN; ANTIGESTAGEN; ESTRADIOL; ESTROGEN RECEPTOR; MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN;

ANALYSIS OF VARIANCE; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; EXPLANT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN SECRETION; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; DRUG SYNERGISM; ESTRADIOL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIFEPRISTONE; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TISSUE CULTURE TECHNIQUES;

EID: 15944378914     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ghir.2004.12.006     Document Type: Article

References (38)

1. A. Gompel C. Malet P. Spritzer J.P. Lalardrie F. Kuttenn P. Mauvais-Jarvis Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture J. Clin. Endocrinol. Metab. 63 1986 1174-1180
2. J.M. Cline G. Soderqvist E. von Schoultz L. Skoog B. von Schoultz Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques Am. J. Obstet. Gynaecol. 174 1996 93-100
3. L.J. Hofseth A.M. Raafat J.R. Osuch D.R. Pathak C.A. Slomski S.Z. Haslam Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast J. Clin. Endocrinol. Metab. 84 1999 4559-4565
4. E. Isaksson E. von Schoultz V. Odlind et al. Effects of oral contraceptives on breast epithelial proliferation Breast Cancer Res. Treat. 65 2001 163-169
5. E.L. Gregoraszczuk T. Milewicz J. Kolodziejczyk et al. Progesterone-induced secretion of growth hormone, insulin-like growth factor-I and prolactin by human breast cancer explants Gynecol. Endocrinol. 15 2001 251-258
6. T. Milewicz, K. Augustowska, J. Krzysiek, et al., Progesterone decreases IGFBP-2 and IGFBP-3 secretion by human malignant and non-malignant breast explants increasing IGF-I local bioavailability, in: 10th World Congress of International Society Gynecological Endocrinology, Wrocław, Poland, September 21, 2002
7. T. Milewicz J. Kolodziejczyk J. Krzysiek et al. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor Gynecol. Endocrinol. 16 2002 319-329
8. E. Eppler J. Zapf N. Bailer U.G. Falkmer S. Falkmer M. Reinecke IGF-I in human breast cancer: Low differentiation stage is associated with decreased IGF-I content Eur. J. Endocrinol. 146 2002 813-821
9. M. Raccurt P.E. Lobie E. Moudilou et al. High stromal and epithelial human GH gene expression is associated with proliferative disorders of the mammary gland J. Endocrinol. 175 2002 307-318
10. W. Ruan V. Catanese R. Wieczorek M. Feldman D.L. Kleinberg Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid Endocrinology 136 1995 1296-13302
11. A.J. Stewart B.R. Westley F.E. May Modulation of proliferative response of breast cancer cells to growth factors by oestrogens Br. J. Cancer 66 1992 640-648
12. B.S. Katzenellenbogen M.J. Norman Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen Endocrinology 126 1990 891-898
13. S. Mohan D.J. Baylink IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms J. Endocrinol. 175 2002 19-31
14. Y. Oh H.L. Muller L. Ng R.G. Rosenfeld Transforming growth factor-β induced cell growth inhibition in human breast cancer cells is mediated through IGFBP-3 action J. Biol. Chem. 270 1995 13589-13592
15. Y. Oh H.L. Muller H. Pham R.G. Rosenfeld Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells J. Biol. Chem. 268 35 1993 26045-26048
16. J. Hong G. Zhang F. Dong M.M. Rechler Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells J. Biol. Chem. 277 2002 10489-10497
17. S.M. Zadeh M. Binoux The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene Endocrinology 138 1997 3069-3072
18. D. Yee R.E. Favoni M.E. Lippman D.R. Powell Identification of insulin-like growth factor binding proteins in breast cancer cells Breast Cancer Res. Treat. 18 1 1991 3-10
19. M. Mandala C. Moro G. Ferretti et al. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients Anticancer Res. 21 2001 585-588
20. M.J. Campbell J.V. Woodside J. Secker-Walker A. Titcomb A.J. Leathem IGF status is altered by tamoxifen in patients with breast cancer Mol. Pathol. 54 2001 307-310
21. R.J. Santen J. Pinkerton C. McCartney G.R. Petroni Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy J. Clin. Endocrinol. Metab. 86 2001 16-23
22. M. Bartucci C. Morelli L. Mauro S. Ando E. Surmacz Different insulin-like growth factor I receptor signalling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells Cancer Res. 61 2001 6747-6754
23. H. Salahifar R.C. Baxter J.L. Martin Differential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-beta1 Endocrinology 141 2000 3104-3110
24. D. Yee A.V. Lee Crosstalk between the insulin-like growth factors and estrogens in breast cancer J. Mammary Gland Biol. Neoplasia 5 2000 107-115
25. V. Dubois D. Couissi E. Schonne C. Remacle A. Trouet Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6 MCF-7/AZ and MDA-MB-231 breasts cancer cells. Differential modulation by estrogens in serum-free medium Eur. J. Biochem. 232 1995 47-53
26. H. Huynh X. Yang M. Pollak Estradiol and antiestrogens regulate growth inhibitory insulin like growth factor binding protein 3 autocrine loop in human breast cancer cells J. Biol. Chem. 271 1996 1016-1021
27. J. Krzysiek T. Milewicz K. Augustowska et al. The impact of progesterone on simultanous local secretion of IGFBP-3/IGF-I (IGFBP-3/IGF-I index) by human malignant and non-malignant breast explants depends on tissue steroid receptor phenotype Gin. Pol. 74 9 2003 767-774
28. M.H. Jeng C.J. Parker V.C. Jordan Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation Cancer Res. 52 1992 6539-6546
29. T.W. Chan M. Pollak H. Huynh Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780 Clin. Cancer Res. 7 2001 2545-2554
30. C. Schairer J. Lubin R. Troisi S. Sturgeon L. Brinton R. Hoover Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 283 2000 485-491
31. R.K. Ross A. Paganini-Hill P.C. Wan M.C. Pike Effect of hormone replacement therapy on breast cancer risk: Estrogen versus e Schairer strogen plus progestin J. Nat. Cancer Inst. 92 2000 328-332
32. D.C. Skegg C. Paul G.F. Spears S.M. Williams Progestogen-only oral contraceptives and risk of breast cancer in New Zealand Cancer Causes Control 7 1996 513-519
33. S.M. Corsello C.A. Rota P. Putignano et al. Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer Eur. J. Endocrinol. 139 3 1998 309-313
34. S. Skog Q. He R. Khoshnoud et al. Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line Tumour Biol. 25 1-2 2004 41-47
35. H. Gronbaek V. Tanos D. Meirow et al. Effects of tamoxifen on insulin-like growth factors IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients Anticancer Res. 23 3C 2003 2815-2820
36. H. Yu M.A. Levesque M.J. Khosravi et al. Insulin-like growth factor-binding protein-3 and breast cancer survival Intl. J. Cancer 79 6 1998 624-628
37. R.L. Rocha S.G. Hilsenbeck J.G. Jackson et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival Clin Cancer Res. 3 1 1997 103-109
38. S.J. Moschos C.S. Mantzoros The role of the IGF system in cancer: From basic to clinical studies and clinical applications Oncology 63 2002 317-332